Boehringer Ingelheim

This phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…

This Phase 3 study tests whether adding vicadrostat to the standard drug empagliflozin helps adults with chronic heart failure and a weak heart pump (ejection fraction below 40%). About 4200 participants will take either vicadrostat or a placebo, plus empagliflozin, once daily fo…

This study tests whether empagliflozin, a medicine already used for diabetes, can help children aged 2 to 17 with chronic kidney disease. About 120 kids will take either the drug or a placebo for 6 months, then everyone gets the drug for a year. Researchers will check kidney func…

This study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. …

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This phase 2 trial tests BI 764532 (obrixtamig), an antibody-like drug designed to help the immune system attack cancer cells. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatments. The study compares two…

This study tests the long-term safety of the drug nerandomilast in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). All 1,700 participants have already taken the drug in a previous study. They will take nerandomilast tablets for up to 1 yea…

This study tests a daily pill called BI 1291583 (Verducatib) in 1755 adults and teens with bronchiectasis, a lung condition causing frequent infections and coughing. Participants take either the drug or a placebo for up to 76 weeks. The main goal is to see if the drug reduces the…

This study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …

This study tests an oral medication called BI 1815368 in 300 adults with center-involved diabetic macular edema, a common cause of vision loss in diabetes. Participants take tablets twice daily for about 11 months, and doctors compare vision changes between those on the drug and …

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…

This study tests a new medicine called BI 3812465 for people with diabetic macular edema, a condition that causes swelling in the center of the eye and can lead to vision loss. The trial has two parts: first, a small group gets low to high doses to check safety, then a larger gro…

This study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

This study tests whether adding BI 690517 (Vicadrostat) to empagliflozin can slow kidney disease and prevent heart failure hospitalizations or cardiovascular death in people with chronic kidney disease. About 11,000 adults with or without type 2 diabetes will take either BI 69051…

This study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…

This study tests a new medicine called BI 765423 in 71 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. Participants receive either the drug or a placebo by infusion every four weeks for about 3 months. The main goal is …

This Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…

This study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…

This study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…

This large phase 3 trial is testing whether adding vicadrostat to the existing drug empagliflozin can reduce the risk of heart problems in adults with type 2 diabetes, high blood pressure, and heart disease. About 11,800 participants will take either the combination or a placebo …

This study tests whether adding vicadrostat to the standard medicine empagliflozin helps people with heart failure who have a preserved ejection fraction (heart pumps normally but is stiff). About 6000 adults with symptoms will take either vicadrostat plus empagliflozin or a plac…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This study is testing whether two different versions of the drug survodutide are equally effective in the body. It involves 80 healthy overweight or obese adults who will receive both formulations in a crossover design. The goal is to see if the new formulation matches the origin…

This study tests a new targeted drug called zongertinib, which blocks the HER2 protein that fuels cancer growth, in combination with standard chemotherapy (with or without the immunotherapy pembrolizumab). It is for people with advanced or metastatic non-squamous non-small cell l…

This study tests whether the clot-busting drug tenecteplase can help people who have a stroke more than 4.5 hours ago, including those who wake up with stroke symptoms. About 1,325 adults with brain imaging showing salvageable tissue will be randomly assigned to receive tenectepl…

This study tests a new drug called BI 3032950 in 80 adults with moderate to severe ulcerative colitis who haven't improved on other treatments. In the first part, the drug is given by IV every 4 weeks for 12 weeks. Those who respond then receive injections under the skin every 4 …

This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…

This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …

This early-phase trial tests an experimental drug called BI 765049 in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest dose people can tolerate and to see if the drug helps the imm…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This study tests a drug called nerandomilast in 80 people aged 40+ who have early lung changes and a family history of pulmonary fibrosis. Participants take either the drug or a placebo twice daily for up to 3 years. Doctors monitor lung function and scans to see if the drug slow…

This early-stage study tests whether a new medicine called BI 3031185 is safe and well-tolerated in adults with borderline personality disorder (BPD) or attention-deficit/hyperactivity disorder (ADHD). About 96 participants will receive either the drug or a placebo in a crossover…

This early-stage trial is testing a new drug called BI 3776528 in healthy men aged 18 to 50. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease.

This study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…

This early-stage trial is testing a new drug called BI 3814916 in 136 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood. Thi…

This early-stage study looks at how the experimental drug BI 456906 attaches to receptors in the liver and pancreas that control appetite and weight. About 30 adults with obesity will receive either BI 456906 or the approved weight-loss drug semaglutide for 17 weeks. Researchers …

This early-stage study is testing a new drug called BI 3031185 in 100 healthy adults to see if it is safe and how the body handles it. Participants will take multiple doses of the drug or a placebo. The goal is to gather safety information, not to treat any disease.

This early-stage study is recruiting 44 adults aged 18 to 80, including both healthy people and those with liver problems. All participants will take a single tablet of the drug BI 3000202. Researchers will measure how the drug moves through the body and check for side effects ov…

This early-stage trial checks whether a single dose of vicadrostat changes heart rhythm in 45 healthy adults. Participants receive vicadrostat, placebo, and moxifloxacin (a known heart-rate-affecting drug) in random order. The goal is to see if vicadrostat is safe for the heart b…

This study looks at how interstitial lung disease (ILD) affects people with rheumatic diseases like rheumatoid arthritis and lupus in Mexico. Researchers will track 312 patients over time to see how the lung disease progresses and what factors might make it worse. The goal is to …

This study uses a special PET scan to see how the experimental drug BI 764532 travels through the body and reaches tumors. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers who have run out of standard treatment options. The main goal is to mea…

This early-phase trial is testing a new drug called BI 3821001 in 72 healthy men to see if it is safe and how the body processes it. Participants receive either a single rising dose of the drug or a placebo. The study focuses on side effects and drug levels in the blood, not on t…

This study looks at how pirfenidone changes the amount of a new medicine (BI 1015550) in the blood of adults with idiopathic pulmonary fibrosis (IPF). Twenty participants aged 40 and older will take both drugs over about a month. Researchers will measure blood levels to understan…

This early-stage trial is testing a new drug called BI 3804379 in healthy adults to see if it is safe and how the body processes it. About 106 healthy men and women aged 18 to 65 will receive either the drug or a placebo as a shot under the skin. The study focuses on side effects…